newsfilter
← Latest News
GlobeNewswire·

Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4

ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living